BioNTech斥逾12億美元收購疫苗競爭對手CureVac 後者股價飆近四成
BioNTech(BNTX.US)宣布以約12.5億美元全股票交易收購前新冠疫苗競爭對手CureVac(CVAC.US),以擴展其腫瘤業務。消息公布後,CureVac股價急升39%,BioNTech微升近1%。
CureVac股東將以每股約5.46美元換取BioNTech股份,較CureVac周三收市價溢價34%。交易完成後,CureVac股東將持有BioNTech的4%至6%股份。
CureVac的新冠疫苗在臨床試驗中被證明效果不佳,未能上市,已轉向癌症免疫療法發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.